The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment

Clinical Pharmacology and Therapeutics

Volumn 78, Issue 5, 2005, Pages 551-558

  Fiegenbaum, Marilu ^a   Da Silveira, Fabiano R ^a   Van Der Sand, Cézar R ^a   Van Der Sand, Luiz Carlos ^a   Ferreira, Maria E W ^a   Pires, Renan C ^a   Hutz, Mara H ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ABC TRANSPORTER; ANTILIPEMIC AGENT; CHOLESTEROL; CREATINE KINASE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ENZYME INHIBITOR; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MULTIDRUG RESISTANCE PROTEIN 1; SIMVASTATIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ALLELE; ANAMNESIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FLATULENCE; FOLLOW UP; GENE FREQUENCY; GENE FUNCTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HOMOZYGOTE; HUMAN; HYPERCHOLESTEROLEMIA; LABORATORY TEST; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTRICTION MAPPING; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; TREATMENT OUTCOME; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CYTOCHROME P-450 ENZYME SYSTEM; DNA; FEMALE; HAPLOTYPES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIMVASTATIN; VARIATION (GENETICS);

EID: 28144440151     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2005.08.003     Document Type: Article

References (31)

1. C.J. Vaughan, A.M. Gotto, C.T. Basson The evolving role of statins in the management of atherosclerosis J Am Coll Cardiol 35 2000 1 10
2. R.A. Kreisberg, A. Oberman Lipids and atherosclerosis lessons learned from randomized controlled trials of lipid lowering and other relevant studies J Clin Endocrinol Metab 87 2002 423 437
3. A.H. Maitland-van der Zee, O.H. Klungel, B.H.C. Stricker, W.M.M. Verschuren, J.J.P. Kastelein, H.G.M. Leufkens Genetic polymorphisms importance for response to HMG-CoA reductase inhibitors Atherosclerosis 163 2002 213 222
4. V. Mooser, D.M. Waterworth, T. Isenhour, L. Middleton Cardiovascular pharmacogenetics in the SNP era J Thromb Haemost 1 2003 1398 1402
5. M. Igel, T. Sudhop, K. von Bergmann Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins) Eur J Clin Pharmacol 57 2001 357 364
6. T. Prueksaritanont, L.M. Gorham, B. Ma, L. Liu, X. Yu, J.J. Zhao In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450S Drug Metab Dispos 25 1997 1191 1199
7. J.K. Lamba, Y.S. Lin, E.G. Schuetz, K.E. Thummel Genetic contribution to variable human CYP3A-mediated metabolism Adv Drug Deliv Rev 54 2002 1271 1294
8. P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, J. Schuetz Sequence diversity in CYP3A promoters and characterization of genetic basis of polymorphic CYP3A5 expression Nat Genet 27 2001 383 391
9. E. Wang, C.N. Casciano, R.P. Clement, W.W. Johnson HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein Pharm Res 18 2001 800 806
10. K. Bogman, A.K. Peyer, M. Torok, E. Kusters, J. Drewe HMG-CoA reductase inhibitors and P-glycoprotein modulation Br J Pharmacol 132 2001 1183 1192
11. C. Chen, R.J. Mireles, S.D. Campbell, J. Lin, J.B. Mills, J.J. Xu Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1 Drug Metab Dispos 33 2005 537 546
12. J.F. Rogers, A.N. Nafziger, J.S. Bertino Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs Am J Med 113 2002 746 750
13. C. Marzolini, E. Paus, T. Buclin, R.B. Kim Polymorphisms in human MDR1 (P-glycoprotein) recent advances and clinical relevance Clin Pharmacol Ther 75 2004 13 33
14. B. Tomlinson, P. Chan, W. Lan How well tolerated are lipid-lowering drugs? Drugs Aging 18 2001 665 683
15. I. Hamilton-Craig Statin-associated myopathy Med J Aust 175 2001 486 489
16. N.T. Friedewald, R.I. Levy, D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
17. D.K. Lahiri, J.I. Nurnberger Jr A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies Nucleic Acids Res 19 1991 5444
18. R.L. Roberts, P.R. Joyce, R.T. Mulder, E.J. Begg, M.A. Kennedy A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression Pharmacogenomics J 2 2002 191 196
19. I. Cascorbi, T. Gerloff, A. Johne, C. Meisel, S. Hoffmeyer, M. Schwab Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects Clin Pharmacol Ther 69 2001 169 174
20. R.H.N. Van Schaik, I.P. van der Heiden, J.N. van der Anker, J. Lindemans CYP3A5 variant allele frequencies in Dutch Caucasians Clin Chem 48 2002 1668 1671
21. J.C. Long, R.C. Williams, M. Urbanek An E-M algorithm and testing strategy for multiple locus haplotypes Am J Hum Genet 56 1995 799 810
22. S. Schneider, D. Roessli, L. Excoffier Arlequin ver. 2.000. A software for population genetics data analysis 2000 University of Geneva Geneva (Switzerland)
23. R.C. Lewontin On measures of gametic disequilibrium Genetics 120 1988 849 852
24. R.H. Boger Drug interaction of the statins and consequences for drug selection Int J Clin Pharmacol Ther 39 2001 369 382
25. J. Patel, A.K. Mitra Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs Pharmacogenomics 2 2001 401 405
26. A.H. Schinkel The physiological function of drug-transporting P-glycoproteins Semin Cancer Biol 8 1997 161 170
27. K. Kajinami, M.E. Brousseau, J.M. Ordovas, E.J. Schaefer Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner Am J Cardiol 93 2004 1046 1050
28. S.B. Haga, W. Burke Using pharmacogenetics to improve drug safety and efficacy JAMA 291 2004 2869 2871
29. C.M. Ballantyne, A. Corsini, M.H. Davidson, H. Holdaas, T.A. Jacobson, E. Leitersdorf Risk of myopathy with statin therapy in high-risk patients Arch Intern Med 163 2003 553 564
30. K. Kajinami, M.E. Brousseau, J.M. Ordovas, E.J. Schaefer CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia Am J Cardiol 93 2004 104 107
31. K. Kivisto, M. Niemi, E. Schaefeller, K. Pitkala, R. Tilvis, M.F. Fromm Lipid-lowering response to statins is affected by CYP3A5 polymorphism Pharmacogenetics 14 2004 523 525